<DOC>
	<DOC>NCT01412398</DOC>
	<brief_summary>This study is a regulatory post marketing surveillance in Japan, and it is a local prospective and observational study of patients in continuous cyclic peritoneal dialysis (CCPD) who have received Fosrenol for hyperphosphatemia. The objective of this study is to assess safety and efficacy of using Fosrenol in clinical practice. This study is also all case investigation of which the enrollment period is one year, and all patients in CCPD who received Fosrenol for hyperphosphatemia will be recruited and followed one year.</brief_summary>
	<brief_title>Fosrenol Post-marketing Surveillance for Continuous Cyclic Peritoneal Dialysis in Japan</brief_title>
	<detailed_description />
	<mesh_term>Hyperphosphatemia</mesh_term>
	<criteria>Patients undergoing continuous cyclic peritoneal dialysis who received Fosrenol for hyperphosphatemia Patients who are contraindicated based on the product label</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Fosrenol</keyword>
	<keyword>Hyperphosphatemia</keyword>
	<keyword>Continuous Cyclic Peritoneal Dialysis</keyword>
</DOC>